Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 1.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 356,730 shares of the medical research company’s stock after acquiring an additional 5,807 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in IQVIA were worth $82,479,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 2.0% in the 4th quarter. Nordea Investment Management AB now owns 502,802 shares of the medical research company’s stock valued at $142,358,000 after acquiring an additional 9,722 shares during the last quarter. Gradient Investments LLC boosted its holdings in shares of IQVIA by 15.7% in the 4th quarter. Gradient Investments LLC now owns 60,909 shares of the medical research company’s stock valued at $17,185,000 after acquiring an additional 8,279 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of IQVIA by 2.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 41,495 shares of the medical research company’s stock valued at $11,707,000 after acquiring an additional 821 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of IQVIA by 20.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,131,441 shares of the medical research company’s stock valued at $319,225,000 after acquiring an additional 189,607 shares during the last quarter. Finally, Catalyst Capital Advisors LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $38,000. 87.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE IQV traded up $6.30 during mid-day trading on Thursday, reaching $208.04. The company’s stock had a trading volume of 4,394 shares, compared to its average volume of 1,002,427. The stock has a 50-day moving average of $213.11 and a two-hundred day moving average of $233.86. The stock has a market capitalization of $39.38 billion, a P/E ratio of 36.35, a P/E/G ratio of 1.42 and a beta of 1.41. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.93 and a current ratio of 0.93. IQVIA Holdings Inc. has a 1-year low of $194.67 and a 1-year high of $285.61.

IQVIA (NYSE:IQVGet Rating) last issued its earnings results on Wednesday, April 27th. The medical research company reported $2.34 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.07. The business had revenue of $3.57 billion during the quarter, compared to analysts’ expectations of $3.54 billion. IQVIA had a net margin of 7.69% and a return on equity of 28.80%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.05 earnings per share. Analysts predict that IQVIA Holdings Inc. will post 9.48 EPS for the current fiscal year.

Several equities analysts recently issued reports on IQV shares. Guggenheim started coverage on shares of IQVIA in a research note on Monday, May 23rd. They issued a “buy” rating and a $244.00 target price for the company. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Barclays decreased their target price on shares of IQVIA from $275.00 to $240.00 in a research note on Thursday, April 28th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of IQVIA from $250.00 to $290.00 and gave the company a “buy” rating in a research note on Tuesday, April 12th. Finally, Mizuho decreased their target price on shares of IQVIA from $300.00 to $270.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Two research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $277.80.

IQVIA Company Profile (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.